More protection against variants such as Omicron, Moderna releases clinical data of the first bivalent mRNA new crown vaccine (Phase 2/3)

Recently (April 19, 2022), Moderna published the latest phase II/III clinical data of its bivalent mRNA new crown vaccine mRNA-1273.
211 on Research Square
.

Tests have shown that this bivalent mRNA new crown vaccine can be used as a booster to more effectively target new coronavirus variants (beta, delta, omicron)
.

mRNA-1273.
211 is a mixed vaccine of mRNA-1273 and mRNA-1273.
351 (1:1) launched by Moderna
.

mRNA-1273 is an mRNA new crown vaccine against the original virus strain SARS-CoV-2, and mRNA-1273.
351 is an mRNA new crown vaccine developed against its variant beta
.

The Phase II/III clinical trial announced today focused on evaluating the safety and immunogenicity of mRNA-1273.
211 as a booster in two dose groups [50-µg (n=300) and 100-µg (n=595)]
.

Results of clinical assays showed higher neutralizing antibody titers were produced one month and six months after vaccination with mRNA-1273.
211 compared to mRNA-1273, the currently used mRNA new crown vaccine against the original virus strain SARS-CoV-2
.

One month after the subjects received the 50µg mRNA-1273.
211 booster, neutralizing antibody titers against the omicron variant were 2.
2 times higher than the 50µg mRNA-1273 booster
.

Six months after inoculation, 50µg mRNA-1273.
211 was still more resistant (2.
15-fold) to the omicron variant than the 50µg mRNA-1273 booster
.

Additionally, this bivalent vaccine induced higher neutralizing antibody responses against variants not explicitly included in the vaccine
.

The 50µg/100µg mRNA-1273.
211 booster induced higher neutralizing antibody responses against SARS-CoV-2 and delta compared to the mRNA-1273 booster
.

In terms of safety, the incidence of adverse reactions of mRNA-1273.
211 was comparable to that of mRNA-1273 (50-µg)
.

There were no adverse events of death and SAEs associated with mRNA-1273.
211 or adverse events leading to clinical discontinuation of mRNA-1273.
211
.

Common local adverse reactions within 7 days of mRNA-1273.
211 (50-µg) vaccination were pain (85%), and common systemic adverse reactions were fatigue (64%), headache (51%), and myalgia (49%)
.

The 100-µg mRNA-1273.
21 had a higher incidence of adverse reactions compared to the 50-µg mRNA-1273.
211
.

The common local adverse reactions in the 100-µg dose group mRNA-1273.
21 at 7 days were pain (91%), and the common systemic adverse reactions were fatigue (70%), headache (56%), and myalgia (56%)
.

In addition to mRNA-1273.
211, Moderna currently has a bivalent mRNA new crown vaccine candidate called mRNA-1273.
214 that is currently in clinical advancement.
mRNA-1273.
214 consists of mRNA-1273 (Spikevax) and mRNA new crown vaccine mRNA for Omicron variants -1273.
529 composition
.

Moderna is scheduled to launch as a booster shot this fall
.

mRNA-1273.
214 is currently being evaluated in Phase 2/3 clinical trials, and the first subject vaccination has been completed in early March this year, and preliminary clinical data will be announced in the second quarter of this year
.

The editor concluded that SARS-CoV-2 variant strains have caused many new crown epidemics around the world
.

The mRNA vaccine against the original new coronavirus has limited resistance to several currently circulating variant strains
.

The duration of protective efficacy of the vaccine may be shortened more quickly, and the neutralization titer against the variant virus (6-8 months) drops rapidly
.

The launch of the bivalent mRNA vaccine booster may become a powerful tool for dealing with new mutants
.

Reference https://doi.
org/10.
21203/rs.
3.
rs-1555201/v1http:// article/moderna-s-new-bivalent-booster-proves-more-effective-vs-covid-19/https:// covid-19-booster-platform/?keywords=Modernahttps://endpts.
com/covid-19-roundup-moderna-showcases-progress-on-its-bivalent-booster-novavax-wins-approval-in-japan/